Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
Volume 0.15M
Average 0.49M
PLRX Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Pliant Therapeutics, Inc.NASDAQ: PLRX
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments falls 30.4% from a year ago
Short-term investments stood at $148.7M at the end of Q1 FY2026, down 30.4% from a year earlier and up 2.2% from the prior quarter. Over 3 fiscal years it compounded at -21.2% a year.
Context
- Short-term investments amounted to 73.4% of total assets at the end of Q1 FY2026, up 11.4 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps falling in the next quarterly balance sheet after a -30.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 145.5M USD
- Year-over-year change
- -48.9%
- 4-year CAGR
- -0.6%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 145.5M | -48.9% |
| FY2024 | 2024-12-31 | 284.54M | -34.0% |
| FY2023 | 2023-12-31 | 431.01M | +44.9% |
| FY2022 | 2022-12-31 | 297.5M | +99.8% |
| FY2021 | 2021-12-31 | 148.93M | — |
Short-term Investments vs competitors
How PLRX compares with its peers on the latest reported figures
- PLRX's Mar 2026 short-term investments of $148.7M is the 2nd highest of the 10 companies compared; the peer median is $65.83M.
- Its year-over-year change of -30.4% is the 5th highest of 7, against a peer median of +85.7%.
- Short-term investments amounts to 73.4% of total assets for PLRX, versus a peer median of 40.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $179.83M | -38.1% | -19.0% | 71.1% | |
| Mar 2026 | $148.7M | -30.4% | -21.2% | 73.4% | |
| Mar 2026 | $128.88M | -9.7% | -33.8% | 53.3% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $88.25M | +2426.6% | -6.8% | 69.4% |
| Mar 2026 | $87.71M | +923.4% | +42.9% | 40.3% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $65.83M | -51.4% | — | 62.1% |
| Mar 2026 | $61.46M | +181.1% | -12.4% | 27.2% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding PLRX) | $65.83M | +85.7% | -12.4% | 40.3% | |
Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 51.67M | 33.69M | 63.23M | 71.19M | 45.45M |
| Short-term Investments | 148.93M | 297.5M | 431.01M | 284.54M | 145.5M |
| Net Receivables | 2.47M | 3.14M | 3M | 2.3M | 823K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 156K | 173K | 1.27M | 163K | 1.13M |
| Total Current Assets | 209.44M | 340.31M | 505.5M | 362.26M | 196.45M |
| Property, Plant & Equipment (Net) | 10.94M | 9.91M | 4.78M | 32.77M | 25.01M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 838K | 394K | 1.87M | 1.92M | 3.77M |
| Total Non-current Assets | 11.77M | 10.3M | 6.65M | 34.69M | 28.78M |
| Total Assets | 221.22M | 350.61M | 512.15M | 396.95M | 225.23M |
| Account Payables | 2.97M | 1.58M | 4.53M | 5.96M | 480K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 5.22M | 7.2M | 9.04M | 11.15M | 8.3M |
| Total Current Liabilities | 16.83M | 23.91M | 28.52M | 33.22M | 16.37M |
| Long-term Debt | 0 | 9.93M | 10.05M | 30.21M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 5.33M | 13.36M | 10.05M | 59.65M | 27.66M |
| Total Liabilities | 22.16M | 37.27M | 38.58M | 92.87M | 44.02M |
| Common Stock | 3K | 5K | 6K | 6K | 6K |
| Retained Earnings | (215.09M) | (338.41M) | (499.75M) | (710.05M) | (859.4M) |
| Accumulated OCI | (201K) | (1.96M) | 345K | 321K | (15K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 199.06M | 313.34M | 473.58M | 304.08M | 181.21M |
| Total Debt | 7.19M | 15.82M | 11.37M | 60.19M | 29.11M |
| Net Debt | (44.47M) | (17.87M) | (51.86M) | (11M) | (16.34M) |
Pliant Therapeutics, Inc.
NASDAQ:PLRX
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.